Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person
Basel, 24 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure prophylaxis.“With today’s approval, Xofluza is now available as the first single-dose, post-exposure preventive treatment for influenza,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We’re hopeful that reducing the burden of influenza may he lp to mitigate the strain on our healthcare system amid the COVID-19 pandemic.” Post-exposure prophylaxis with single-dose Xofluza was evaluated in the phase III BLOCKSTONE study, which was recently published in The New England Journal of Medicine.1 BLOCKSTONE evaluated Xofluza compared with placebo as a preventive treatment for household members (adults and children) who were living with someone with influenza. Xofluza showed a statistically significant prophylactic effect on influenza after a single oral dose in people exposed to an infected household contact. The proportion of household members 12 years of age and older who developed influenza was 1% in participants treated with Xofluza and 13%...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Allergy & Immunology | Biotechnology | Bird Flu | Bird Flu (H5N1 Avian Influenza) Vaccine | Bronchitis | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer Vaccines | Child Development | Children | Coronavirus | COVID-19 | Diabetes | Diarrhoea | Endocrinology | Epidemics | Epidemiology | Flu Pandemic | Food and Drug Administration (FDA) | H5N1 | Headache | Infectious Diseases | Influenza | Influenza Vaccine | International Medicine & Public Health | Internet | Japan Health | Laboratory Medicine | Men | Migraine | New Drug Applications | Opthalmology | Oral Cancer | Oseltamivir | Pandemics | Pediatrics | Pharmaceuticals | Respiratory Medicine | SARS | Science | Sinusitis | Statistics | Study | Switzerland Health | Taiwan Health | Tamiflu | Urology & Nephrology | USA Health | Vaccines | WHO